BTC	biliary tract cancer
ICI	immune-checkpoint inhibitors
iCCA	intrahepatic cholangiocarcinoma
eCCA	extrahepatic cholangiocarcinoma
GB	gallbladder cancer
CCA	cholangiocarcinoma
FDG-PET	18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography
OS	overall survival
PD-1/PDL-1	programmed cell death protein-1/ligand-1
MSI	microsatellite instability
TMB	tumor mutational burden
TME	tumor microenvironment
FDA	food and drug administration
PFS	progression-free survival
TP53	tumor protein p53
BRCA2	breast cancer gene
Chemo-IO	chemo-immunotherapy
KRAS	Kirsten rat sarcoma
ARID1	at-rich interaction domain 1A
CTLA-4	cytotoxic T-lymphocyte antigen-4
ctDNA	circulating tumor DNA
ORR	overall response rate
CPS	combined positive score
DCR	disease control rate
IDH1	isocitrate dehydrogenase 1
FGFR2	fibroblast growth factor receptor 2
MAPK	mitogen-activated protein kinase
MEK	methyl ethyl ketone
BRAF	B-Raf-proto-oncogene
Her2	Human epidermal growth factor receptor 2
RTK	receptor tyrosine kinase
PARPi	Poly (ADP-ribose) polymerase inhibitors
PR	partial response
VEFG	vascular endothelial growth factor
APC	antigen-presenting cells
TIM3	T-cell immunoglobulin and mucin domain-3
LAG4	lymphocyte-activation gene 3
RFS	relapse-free survival
CEA	carcinoma embryonic antigen